Chemotargets and the CRG ally to accelerate the development of new treatments

by Centre for Genomic Regulation

3 years ago
Drug, Chemotargets, Centre for Genomic Regulation, therapies

Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet ...

CRG publishes findings of its first public dialogue with Spanish civil society

by Centre for Genomic Regulation

3 years ago
Centre for Genomic Regulation, biomedical research

The Centre for Genomic Regulation (CRG) has today published the findings of a report exploring the in-depth views of civil society, funders, journalists, policymakers and other key collaborators in...

CNAG-CRG joins forces with US institutions to set up new genome imaging centre at Harvard

by Centre for Genomic Regulation

3 years ago
Centro Nacional de Análisis Genómico, Centre for Genomic Regulation

The Centro Nacional de Análisis Genómico (CNAG-CRG), part of the Centre for Genomic Regulation (CRG) in Barcelona, will be part of the Center for Genome Imaging, a new infrastructure based at Harvar...

New members and focus on the CRG Business Board

by Centre for Genomic Regulation

9 years ago
CRG, Centre for Genomic Regulation

CRG Technology and Business Development Office has redefined its priorities and the way it brings innovative ideas to the market, launching several new programs and activities to promote commercializa...

Six top Catalan research centres constitute 'The Barcelona Institute of Science and Technology' to pursue a joint scientific endeavour

by IRB Barcelona - Instituto de Investigación Biomédica

The Barcelona Institute emerges as one of the leading scientific institutes in Europe, ranking fourth in the number of ERC grants awarded per volume of researchers

'Spark', a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

by IRB Barcelona - Instituto de Investigación Biomédica

10 years ago
Spark, Iproteos, Centre for Genomic Regulation, IRB Barcelona, schizophrenia

The expected end-result will be the obtaining of an optimal formulation and a route of administration of the compound for its use as a drug in patients. This will allow carrying out the regulatory pre...